Article

A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease.

Department of Biochemistry, The Hopkins Building, Tennis Court Road, University of Cambridge, Cambridge CB21QW, UK.
Neurochemistry International (Impact Factor: 2.65). 07/2010; 56(8):937-47. DOI: 10.1016/j.neuint.2010.04.001
Source: PubMed

ABSTRACT Alzheimer's disease is the most common neurodegenerative disease of the central nervous system characterized by a progressive loss in memory and deterioration of cognitive functions. In this study the transgenic mouse TgCRND8, which encodes a mutant form of the amyloid precursor protein 695 with both the Swedish and Indiana mutations and develops extracellular amyloid beta-peptide deposits as early as 2-3 months, was investigated. Extract from eight brain regions (cortex, frontal cortex, cerebellum, hippocampus, olfactory bulb, pons, midbrain and striatum) were studied using (1)H NMR spectroscopy. Analysis of the NMR spectra discriminated control from APP695 tissues in hippocampus, cortex, frontal cortex, midbrain and cerebellum, with hippocampal and cortical region being most affected. The analysis of the corresponding loading plots for these brain regions indicated a decrease in N-acetyl-L-aspartate, glutamate, glutamine, taurine (exception hippocampus), gamma-amino butyric acid, choline and phosphocholine (combined resonances), creatine, phosphocreatine and succinate in hippocampus, cortex, frontal cortex (exception gamma-amino butyric acid) and midbrain of affected animals. An increase in lactate, aspartate, glycine (except in midbrain) and other amino acids including alanine (exception frontal cortex), leucine, iso-leucine, valine and water soluble free fatty acids (0.8-0.9 and 1.2-1.3 ppm) were observed in the TgCRND8 mice. Our findings demonstrate that the perturbations in metabolism are more widespread and include the cerebellum and midbrain. Furthermore, metabolic perturbations are associated with a wide range of metabolites which could improve the diagnosis and monitoring of the progression of Alzheimer's disease.

0 Bookmarks
 · 
273 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The transgenic mouse APP/PS1 is widely employed by neuroscientists because reproduces well some of the neuropathological and cognitive deficits observed in human Alzheimer's disease. In this study, serum samples from APP/PS1 mice (n = 30) and wild-type controls (n = 30) were analyzed using a metabolomic multiplatform based on the combination of gas chromatography-mass spectrometry and ultra-high performance liquid chromatography-mass spectrometry, in order to obtain wide information about serum metabolome. Metabolic profiles showed significant differences between the groups of study, and numerous metabolites were identified as potential players in the development of Alzheimer-type disorders in this transgenic model. Pathway analysis revealed the involvement of multiple metabolic networks in the underlying pathology, such as deficiencies in energy metabolism, altered amino acid homeostasis, abnormal membrane lipid metabolism, and other impairments related to the integrity of the central nervous system. It is noteworthy that some of these metabolomic markers are in accordance with pathological alterations observed in human Alzheimer's disease, while others have not been previously described. Therefore, these results demonstrate the potential of metabolomics and the use of transgenic animal models to understand the pathogenesis of Alzheimer's disease. Copyright © 2015 Elsevier B.V. and Sociétéfrançaise de biochimie et biologie Moléculaire (SFBBM). All rights reserved.
    Biochimie 01/2015; · 3.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most common cause of dementia worldwide. As advancing age is the greatest risk factor for developing AD, the number of those afflicted is expected to increase markedly with the aging of the world's population. The inability to definitively diagnose AD until autopsy remains an impediment to establishing effective targeted treatments. Neuroimaging has enabled in vivo visualization of pathological changes in the brain associated with the disease, providing a greater understanding of its pathophysiological development and progression. However, neuroimaging biomarkers do not yet offer clear advantages over current clinical diagnostic criteria for them to be accepted into routine clinical use. Nonetheless, current insights from neuroimaging combined with the elucidation of biochemical and molecular processes in AD are informing the ongoing development of new imaging techniques and their application. Much of this research has been greatly assisted by the availability of transgenic mouse models of AD. In this review we summarize the main efforts of neuroimaging in AD in humans and in mouse models, with a specific focus on β-amyloid, and discuss the potential of new applications and novel approaches.
    Frontiers in Neuroscience 10/2014; 8:327.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The identification of pathological mechanisms underlying to Alzheimer's disease is of great importance for the discovery of potential markers for diagnosis and disease monitoring. In this study, we investigated regional metabolic alterations in brain from the APP/PS1 mice, a transgenic model that reproduces well some of the neuropathological and cognitive deficits observed in human Alzheimer's disease. For this purpose, hippocampus, cortex, cerebellum and olfactory bulbs were analyzed using a high-throughput metabolomic approach based on direct infusion mass spectrometry. Metabolic fingerprints showed significant differences between transgenic and wild-type mice in all brain tissues, being hippocampus and cortex the most affected regions. Alterations in numerous metabolites were detected including phospholipids, fatty acids, purine and pyrimidine metabolites, acylcarnitines, sterols and amino acids, among others. Furthermore, metabolic pathway analysis revealed important alterations in homeostasis of lipids, energy management, and metabolism of amino acids and nucleotides. Therefore, these findings demonstrate the potential of metabolomic screening and the use of transgenic models for understanding pathogenesis of Alzheimer's disease. Copyright © 2014 Elsevier B.V. All rights reserved.
    Journal of Pharmaceutical and Biomedical Analysis 10/2014; 102C:425-435. · 2.83 Impact Factor

Full-text (3 Sources)

Download
205 Downloads
Available from
May 30, 2014